During the past decade, Tokyo Bay Urayasu Ichikawa Medical Center conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 2 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Bay Urayasu Ichikawa Medical Center" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Abbott Medical Devices" with 1 trials sponsored, "Bayer" with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Ottawa Heart Institute Research Corporation" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Bay Urayasu Ichikawa Medical Center" #1 collaborator was "Abbott" with 1 trials as a collaborator, "Apollo Hospitals Enterprise Limited" with 1 trials as a collaborator, "Carolinas Medical Center" with 1 trials as a collaborator, "Far Eastern Memorial Hospital" with 1 trials as a collaborator and "Fortis Escorts Heart Institute" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Bay Urayasu Ichikawa Medical Center" are "Alzheimer Disease" (2 trials), "Coronary Artery Disease" (1 trials), "Endometriosis" (1 trials), "Mitral Regurgitation" (1 trials) and "Mitral Valve Regurgitation" (1 trials). Many other conditions were trialed in "Tokyo Bay Urayasu Ichikawa Medical Center" in a lesser frequency.

Most popular intervention types in "Tokyo Bay Urayasu Ichikawa Medical Center" are "Drug" (3 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gantenerumab" (2 trials), "Placebo" (2 trials), "BAY1817080" (1 trials), "Conventional CABG" (1 trials) and "Elagolix" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Bay Urayasu Ichikawa Medical Center" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Tokyo Bay Urayasu Ichikawa Medical Center". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Tokyo Bay Urayasu Ichikawa Medical Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Bay Urayasu Ichikawa Medical Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".